Table 4 36 up- and downregulated common DEGs in B16 melanoma shared by PCSK9-WT and D374Y in comparison to control

Eda2r

ectodysplasin A2 receptor

1.46^a, 1,75^b

EDA2R expression was negatively correlated with prognosis

[69]

Ldhd*

lactate dehydrogenase D

1.34, 1,45

NA

Car3*

carbonic anhydrase 3

1.09, 3.28

NA

Arg1*

arginase

1.09, 2.36

Enhancing activities promoting melanoma

[70]

Cnr2*

carbonyl reductase 2

1.05, 1.44

NA

Cd5l

CD5 antigen-like

0.96, 2.99

NA

Agap2*

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

0.95, 1.13

Identified as part of a 6-gene prognostic factor for melanoma patients, AGAP2 was highly expressed in melanoma tissues compared with normal healthy control (p < 0.05, Student’s t-test, n = 10)

[71]

Gm16316

predicted gene 16316

0.95, 1.68

NA

Serpinb8*

serine (or cysteine) peptidase inhibitor, clade B, member 8

0.87, 2.19

NA

Gpx3

glutathione peroxidase 3

0.87, 1.90

Inhibition of melanoma via inhibiting HIF1-α; negative association with poor prognosis in melanoma patients

[72]

Epha5

Eph receptor A5

0.84, 1.99

High EphA5 expression is associated with longer overall survival time

[73]

H19

H19, imprinted maternally expressed transcript

0.83, 1.89

Facilitating melanoma pathogenesis

[74]

Fcgr2b*

Fc receptor, IgG, low affinity IIb

0.83, 1.85

Suppressing CD8 + T cells-derived cytotoxic actions in patients with melanoma

[75]

Omg*

oligodendrocyte myelin glycoprotein

0.83, 2.22

NA

Cryzl2

crystallin zeta like 2

0.83, 1.80

NA

Sgk1*

serum/glucocorticoid regulated kinase 1

0.81, 1.12

Facilitating CD4 + cell differentiation via regulating IL4 and IFN-γ

[76]

Gimap7*

GTPase, IMAP family member 7

0.80, 1.56

NA

Slco2a1

solute carrier organic anion transporter family, member 2a1

0.78, 1.53

NA

Il33*

interleukin 33

0.78, 1.45

Likely contributing to immunosuppressive TME in metastatic melanoma

[77]

Tbc1d9*

TBC1 domain family, member 9

0.77, 1.37

NA

Dapk1*

death associated protein kinase 1

0.76, 1.50

A pro-apoptotic factor in melanoma cells

[78]

Loxl1

lysyl oxidase-like 1

0.76, 1.62

NA

F7

coagulation factor VII

0.73, 3.68

NA

Gas6

growth arrest specific 6

0.72, 1.71

Facilitating activation of MAPK/ERK, PI3K/Akt and JAK/STAT

[79]

Selenop (SELP)*

selenoprotein P

0.70, 1.02

NA

Saa3

serum amyloid A 3

0.70, 2.53

NA

Lbp*

lipopolysaccharide binding protein

0.70, 1.97

NA

Dpp4*

dipeptidylpeptidase 4

0.66, 1.58

Loss of DPP4 associates with melanoma progression

[80]

Cyp27a1*

cytochrome P450, family 27, subfamily a, polypeptide 1

0.60, 2.63

Cyp27a1 is a transcriptional target of melanogenesis-associated transcription factor (MITF). Cyp27a1 is necessary for the generation of a reactive metabolite that inhibits cellular proliferation in melanoma

[81]

Itga6*

integrin alpha 6

-0.63, -1.38

Decrease in metastatic SKCM tissues correlates with immune cell infiltration; Iga6 expression was also remarkably negatively correlated with overall survival in SKCM patients

[82]

Scn1a

sodium channel, voltage-gated, type I, alpha

-0.81, 1.19

NA

Tenm4

teneurin transmembrane protein 4

-0.82, -2.50

Lower TENM4 mRNA levels have been observed in skin cutaneous melanoma (TCGA dataset & GTEx project) compared to normal tissues

[83]

Garnl3

GTPase activating RANGAP domain-like 3

-0.93, -1.67

NA

Slc4a4

solute carrier family 4 (anion exchanger), member 4

-0.95, -2.23

NA

Tnfrsf9*

tumor necrosis factor receptor superfamily, member 9

-0.97, -1.61

As a costimulatory receptor in immune cells, TNFRSF9 enhances immune cell infiltration. Furthermore, elevated TNFRSF9 mRNA expression and TNFRSF9 hypomethylation correlated with improved overall survival. In patients receiving anti-PD-1 immunotherapy, reductions of TNFRSF9 correlated with poor response

[84]

Miga1

mitoguardin 1

-2.52, -3.71

NA